--- title: "Sun-Novo: BTP4507 has received the notification of approval for clinical trials" type: "News" locale: "en" url: "https://longbridge.com/en/news/260772618.md" description: "According to the Zhitong Finance APP, Sun-Novo announced that its subsidiary Jiangsu Novo Biotech Co., Ltd. has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy" datetime: "2025-10-12T08:34:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/260772618.md) - [en](https://longbridge.com/en/news/260772618.md) - [zh-HK](https://longbridge.com/zh-HK/news/260772618.md) --- # Sun-Novo: BTP4507 has received the notification of approval for clinical trials According to the Zhitong Finance APP, Sun-Novo (688621.SH) announced that its subsidiary Jiangsu Novo Biotech New Drug Research and Development Co., Ltd. has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy ### Related Stocks - [688621.CN](https://longbridge.com/en/quote/688621.CN.md) ## Related News & Research - [$1000 Invested In SPDR Gold MiniShares Trust 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286819467.md) - [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md) - [Boardwalk REIT announces availability of 2025 ESG report](https://longbridge.com/en/news/287130104.md) - [Always-on fraud checks cut Suncoast's losses by a third](https://longbridge.com/en/news/286815368.md) - [09:47 ETSun Auto Increases Presence in Illinois with Recent Acquisition](https://longbridge.com/en/news/287078053.md)